文献速递免疫规划

Biological E公司CORBEVAX™疫苗在儿童与青少年中的安全性、耐受性与免疫原性:一项前瞻性、随机、双盲、安慰剂对照的2/3期研究

Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
PubMed 文献 · Vaccine · 2022-10-31

本研究为2/3期前瞻性、随机、双盲、安慰剂对照研究,评估CORBEVAX™疫苗在5至<18岁儿童与青少年中的安全性、反应原性、耐受性和免疫原性,受试者按3:1随机接种疫苗或安慰剂。结果显示疫苗组不良事件多为轻度,未报告严重不良事件、需就医不良事件或特别关注不良事件,且抗RBD-IgG、中和抗体滴度及干扰素-γ免疫反应显著升高。

要点

  • CORBEVAX™疫苗在5至<18岁儿童与青少年中安全性良好,不良事件多为轻度。
  • 研究期间未报告严重不良事件、需就医不良事件或特别关注不良事件。
  • 疫苗组抗RBD-IgG、中和抗体滴度及干扰素-γ反应显著升高,中和抗体滴度非劣于成人队列。

核心结论

  • CORBEVAX™疫苗在<18至≥5岁儿童与青少年中被认为安全且可耐受。
  • 接种后两个儿科年龄亚组均观察到抗RBD-IgG和中和抗体滴度及干扰素-γ免疫反应显著增加。
  • 两个儿科年龄队列的中和抗体滴度在GMT比值方面非劣于成人队列(BECT069研究)。
  • CORBEVAX™疫苗具有高度免疫原性,可安全用于低至5岁的儿科人群。

研究设计与样本

  • 本研究为2/3期前瞻性、随机、双盲、安慰剂对照研究。
  • 研究对象为<18至≥12岁(2期)及<18至≥5岁(2/3期)的儿童与青少年,不限性别,以安慰剂为对照。
  • 研究设两个年龄亚组:亚组1为<18至≥12岁,亚组2为<12至≥5岁。
  • 两个亚组中,符合条件的受试者(基线SARS-CoV-2 RT-PCR阴性且血清阴性)按3:1比例随机接受CORBEVAX™疫苗或安慰剂。
  • 研究在印度临床试验注册中心前瞻性注册,注册号CTRI/2021/10/037066。

主要发现

  • CORBEVAX™疫苗在两个儿科队列中的安全性特征与安慰剂对照组相当。
  • 报告的大多数不良事件为轻度。
  • 研究期间未报告严重不良事件、需就医不良事件或特别关注不良事件,所有报告的不良事件均无后遗症地缓解。
  • 两个儿科年龄组中,CORBEVAX™疫苗接种者在抗RBD-IgG浓度、抗RBD-IgG1滴度、针对原始武汉株和Delta株的中和抗体滴度方面均显示体液免疫反应显著改善。
  • CORBEVAX™疫苗接种者诱发了显著高的干扰素-γ免疫反应(细胞免疫),对IL-4细胞因子分泌影响极小。

临床怎么用

  • 作者认为CORBEVAX™疫苗具有高度免疫原性,可安全用于低至5岁的儿科人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After establishing safety and immunogenicity of Biological-E's CORBEVAX™ vaccine in adult population (18-80 years) in Phase 1-3 studies, vaccine is further tested in children and adolescents in this study. METHODS: This is a phase-2/3 prospective, randomised, double-blind, placebo-controlled study evaluating safety, reactogenicity, tolerability and immunogenicity of CORBEVAX™ vaccine in children and adolescents of either gender between <18 to ≥12 years of age in Phase-2 and <18 to ≥5 years of age in Phase-Phase-2/Phase-3 with placebo as a control. This study has two age sub-groups; subgroup-1 with subjects <18 to ≥12 years of age and subgroup-2 with subjects <12 to ≥5 years of age. In both sub groups, eligible subjects (SARS-CoV-2 RT-PCR negative and seronegative at baseline) were randomized to receive either CORBEVAX™ vaccine or Placebo in 3:1 ratio. FINDINGS: The safety profile of CORBEVAX™ vaccine in both pediatric cohorts was comparable to the placebo-control group. Majority of reported adverse events (AEs) were mild in nature. No severe or serious-AEs, medically attended AEs (MAAEs) or AEs of special interest (AESI) were reported during the study period and all reported AEs resolved without any sequelae. In both pediatric age groups, CORBEVAX™ vaccinated subjects showed significant improvement in humoral immune-responses in terms of anti-RBD-IgG concentrations, anti-RBD-IgG1 titers, neutralizing-antibody (nAb)-titers against Ancestral-Wuhan and Delta-strains. Significantly high interferon-gamma immune- response (cellular) was elicited by CORBEVAX™ vaccinated subjects with minimal effect on IL-4 cytokine secretion. INTERPRETATIONS: The safety profile of CORBEVAX™ vaccine in <18 to ≥5 years' children and adolescents was found to be safe and tolerable. Significant increase in anti-RBD-IgG and nAb-titers and IFN-gamma immune-responses were observed post-vaccination in both pediatric age sub-groups. The nAb titers observed in both the pediatric age cohorts were non-inferior to the adult cohort (BECT069 study) in terms of ratio of the GMT's of both the cohorts. This study shows that CORBEVAX™ vaccine is highly immunogenic and can be safely administered to pediatric population as young as 5 years old. The study was prospectively registered with clinical trial registry of India- CTRI/2021/10/037066.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thuluva S, Paradkar V, Gunneri S, et al. Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. Vaccine. 2022. PMID: 36328879. doi:10.1016/j.vaccine.2022.10.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。